Advertisement
Abstracts and information about the AACR and its Annual Meeting may befound at http://www.aacr.org.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with aportfolio of innovative product candidates in clinical trials for thetreatment of cancer and hepatitis C virus (HCV) infection. The company ispursuing three separate clinical programs in cancer and HCV infection with itslead product candidates bavituximab and Cotara(R). Peregrine also has in-housemanufacturing capabilities through its wholly owned subsidiary AvidBioservices, Inc. (http://www.avidbio.com), which provides development andbio-manufacturing services for both Peregrine and outside customers.Additional information about Peregrine can be found athttp://www.peregrineinc.com.-- "Targeting mutant p53 protein and tumor vasculature: An effective combination therapy for advanced breast tumors" (Abstract #2341, New Targets 1: Mechanisms Session) - Poster session scheduled for Monday, April 14, 2008 from 8:00 am to 12:00 pm. -- "An immunocytokine that binds to phosphatidylserine generates an effective cell-based tumor vaccine in mice" (Abstract #2841, Tumor Vaccines Session) - Poster session scheduled for Monday, April 14, 2008 from 1:00 pm to 5:00 pm. -- "Combination of a monoclonal anti-phosphatidylserine antibody with docetaxel strongly inhibits the growth and metastasis of hormone-refractory prostate cancers in mice" (Abstract #2551, New Approaches to Biological Therapy Session) - Oral presentation scheduled for Monday, April 14, 2008 at 2:10 pm. -- "Antibody targeting of phosphatidylserine produces a cytokine microenvironment that enhances innate anti-tumor immune responses" (Abstract #4079, Immunoconjugates, Peptides, and Protein Therapeutics Session) - Poster session scheduled for Tuesday, April 15, 2008 from 8:00 am to 12:00 pm.
SOURCE Peregrine Pharmaceuticals, Inc.